Summary & Overview
HCPCS Q9983: Florbetaben F18 PET Diagnostic Study Dose
HCPCS Level II code Q9983 denotes florbetaben F18, billed per study dose (up to 8.1 millicuries), for diagnostic PET imaging typically used in visualization of cerebral amyloid. This radiopharmaceutical code matters nationally because PET amyloid imaging has implications for diagnostic pathways in cognitive disorders and for payer coverage determinations that affect access to advanced neuroimaging.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of coverage and reimbursement context across major national payers, benchmark metrics where available, and the relevant clinical context for use of florbetaben F18 in PET studies.
The publication outlines the clinical indication and service setting for the code, typical billing considerations, and comparisons of payer approaches to covering amyloid PET agents. It also summarizes policy and coding factors that affect utilization and claims processing for radiopharmaceutical diagnostic doses. Data not available in the input is clearly noted where applicable.
Billing Code Overview
HCPCS Level II code Q9983 represents Florbetaben F18, administered for diagnostic PET imaging, billed per study dose, up to 8.1 millicuries. The service type is diagnostic radiopharmaceutical administration for positron emission tomography (PET) imaging, used to assist in imaging of amyloid plaques in the brain. The typical site of service is hospital outpatient departments and imaging centers that provide PET radiopharmaceutical diagnostic studies.
Clinical & Coding Specifications
Clinical Context
A typical patient is an older adult referred by a neurologist or geriatrician for evaluation of suspected Alzheimer disease or other neurodegenerative dementia when amyloid pathology is considered as part of the diagnostic workup. The patient presents with progressive memory decline over months to years, objective cognitive impairment on neuropsychological testing, and equivocal structural imaging (MRI) or atypical presentation where confirmation of cerebral beta-amyloid deposition will inform diagnosis, prognosis, or eligibility for amyloid-targeting therapies.
The clinical workflow: the ordering clinician reviews prior imaging and cognitive testing, obtains informed consent discussing radiopharmaceutical risks and benefits, and schedules the patient for a nuclear medicine PET study. On the day of service, an IV line is placed, and the radiopharmacy or technologist prepares Q9983 (florbetaben F18) up to 8.1 millicuries per study dose. The tracer is administered, uptake time is observed per protocol, and a PET brain acquisition is performed. Images are reviewed by a nuclear medicine physician or radiologist with expertise in brain PET; a formal report documents amyloid uptake pattern, diagnostic impression, and any limitations. The study may be combined with other diagnostic testing in the same episode of care and billed in conjunction with appropriate imaging procedure codes and facility or professional components as indicated.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |